JP2019509253A5 - - Google Patents

Download PDF

Info

Publication number
JP2019509253A5
JP2019509253A5 JP2018532746A JP2018532746A JP2019509253A5 JP 2019509253 A5 JP2019509253 A5 JP 2019509253A5 JP 2018532746 A JP2018532746 A JP 2018532746A JP 2018532746 A JP2018532746 A JP 2018532746A JP 2019509253 A5 JP2019509253 A5 JP 2019509253A5
Authority
JP
Japan
Prior art keywords
phosphate
alaninyl
benzoxy
gemcitabine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018532746A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019509253A (ja
JP6898329B2 (ja
Filing date
Publication date
Priority claimed from PCT/GB2015/054158 external-priority patent/WO2017109444A1/en
Priority claimed from GBGB1609770.1A external-priority patent/GB201609770D0/en
Application filed filed Critical
Priority claimed from PCT/GB2016/054018 external-priority patent/WO2017109486A1/en
Publication of JP2019509253A publication Critical patent/JP2019509253A/ja
Publication of JP2019509253A5 publication Critical patent/JP2019509253A5/ja
Application granted granted Critical
Publication of JP6898329B2 publication Critical patent/JP6898329B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018532746A 2015-12-23 2016-12-21 併用療法 Expired - Fee Related JP6898329B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB2015/054158 WO2017109444A1 (en) 2015-12-23 2015-12-23 Combination therapy
GBPCT/GB2015/054158 2015-12-23
GB1609770.1 2016-06-03
GBGB1609770.1A GB201609770D0 (en) 2016-06-03 2016-06-03 Combination therapy
PCT/GB2016/054018 WO2017109486A1 (en) 2015-12-23 2016-12-21 Combination therapy

Publications (3)

Publication Number Publication Date
JP2019509253A JP2019509253A (ja) 2019-04-04
JP2019509253A5 true JP2019509253A5 (https=) 2020-01-09
JP6898329B2 JP6898329B2 (ja) 2021-07-07

Family

ID=57681677

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018532746A Expired - Fee Related JP6898329B2 (ja) 2015-12-23 2016-12-21 併用療法

Country Status (29)

Country Link
US (2) US20190022117A1 (https=)
EP (2) EP3393478B1 (https=)
JP (1) JP6898329B2 (https=)
KR (1) KR20180096698A (https=)
CN (1) CN108697725A (https=)
AU (1) AU2016375861B2 (https=)
CA (1) CA3008749C (https=)
CY (1) CY1122835T1 (https=)
DK (1) DK3393478T3 (https=)
EA (1) EA037459B1 (https=)
ES (1) ES2778933T3 (https=)
HR (1) HRP20200423T1 (https=)
HU (1) HUE050290T2 (https=)
IL (1) IL260076A (https=)
LT (1) LT3393478T (https=)
MA (1) MA51576A (https=)
MD (1) MD3393478T2 (https=)
ME (1) ME03677B (https=)
MX (1) MX383988B (https=)
MY (1) MY194629A (https=)
PH (1) PH12018501339A1 (https=)
PL (1) PL3393478T3 (https=)
PT (1) PT3393478T (https=)
RS (1) RS60211B1 (https=)
SG (1) SG11201805184TA (https=)
SI (1) SI3393478T1 (https=)
SM (1) SMT202000154T1 (https=)
WO (1) WO2017109486A1 (https=)
ZA (1) ZA201804155B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3150616T1 (sl) 2012-11-16 2017-08-31 University College Cardiff Consultants Limited Mešanica rp/sp gemcitabin-(fenil-(benziloksi-l-alaninil))-fosfata
WO2015198059A1 (en) 2014-06-25 2015-12-30 Nucana Biomed Limited Formulation comprising a gemcitabine-prodrug
EP3160978B1 (en) 2014-06-25 2020-07-29 NuCana plc Gemcitabine prodrugs
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
PH12018500691B1 (en) 2015-10-05 2022-08-10 NuCana plc Combination therapy
RS62593B1 (sr) 2015-12-11 2021-12-31 NuCana plc Dijastereoselektivna sinteza derivata fosfata i proleka gemcitabina nuc-1031
GB201522771D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Crystalline form of a phosphate derivative
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20150258139A1 (en) * 2012-08-13 2015-09-17 Regulon, Inc. Methods for treatment of cancer using lipoplatin
CA2891124A1 (en) * 2012-11-13 2014-05-22 BoYen Therapeutics, Inc. Gemcitabine prodrugs and uses thereof
SMT201800303T1 (it) * 2015-05-14 2018-07-17 NuCana plc Trattamenti per il cancro
PH12018500691B1 (en) * 2015-10-05 2022-08-10 NuCana plc Combination therapy

Similar Documents

Publication Publication Date Title
JP2019509253A5 (https=)
Monneret Platinum anticancer drugs. From serendipity to rational design
KR102301175B1 (ko) 항종양 알칼로이드를 이용한 병용요법
US20180256578A1 (en) A Combination Therapy Comprising Varlitinib and an Anticancer Agent
Chae et al. Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?
JP2019532051A5 (https=)
JP2020535173A5 (https=)
JP2012521435A5 (https=)
HRP20200423T1 (hr) Kombinirana terapija
JP2012506448A5 (https=)
JP2023533464A5 (https=)
JP7193591B2 (ja) 化学療法の改善
JP2014533277A5 (https=)
JP2020523356A5 (https=)
CN102056609B (zh) 药物组合
BR112021007283A2 (pt) método de tratamento de um câncer ou câncer refratário
JP2021505669A5 (https=)
ES2389809T3 (es) Terapias anticancerosas
JP2021528480A5 (https=)
JP2020520385A5 (https=)
ES3027841T3 (en) Miv-818/lenvatinib combination therapy for liver cancer
Hu et al. Current status of CPT and its analogues in the treatment of malignancies
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
JP2024520307A5 (https=)
JP6458007B2 (ja) 抗腫瘍性白金錯体を含有する抗腫瘍剤及び抗腫瘍効果増強剤